- ►diabetesjournals.org DJ Drucker - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP) exert important effects on β-cells to stimulate glucose-dependent
insulin secretion. Both peptides also regulate β-cell proliferation and ... Cited by 283 - Related articles - All 13 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes
population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel
glucose-dependent insulinotropic agent, exhibited notable antidiabetic ... Cited by 275 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum
fructosamine relative to placebo (P ≤ 0.004). Mean reductions ranged from 39
to 46 μmol/l. All AC2993 groups had reductions in HbA 1c ranging from 0.7 ... Cited by 230 - Related articles - BL Direct - All 10 versions
- ►endojournals.org DJ Drucker - Molecular Endocrinology, 2003 - Endocrine Soc Peptide hormones are secreted from endocrine cells and neurons and exert their
actions through activation of G protein-coupled receptors to regulate a diverse
number of physiological systems including control of energy homeostasis, ... Cited by 227 - Related articles - BL Direct - All 8 versions
- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility
and acid secretion, epithelial integrity, and both nutrient absorption and
disposal. These actions are initiated by activation of specific G protein- ... Cited by 216 - Related articles - BL Direct - All 7 versions
- ►endojournals.org L Farilla, A Bulotta, B Hirshberg, S Li Calzi, … - Endocrinology, 2003 - Endocrine Soc The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase
glucose-dependent insulin secretion, enhance insulin gene transcription, expand
islet cell mass, and inhibit ß-cell apoptosis in animal models of ... Cited by 217 - Related articles - BL Direct - All 5 versions
LL Nielsen, AA Young, DG Parkes - Regulatory peptides, 2004 - Elsevier Exenatide (synthetic exendin-4), glucagon-like peptide-1 (GLP-1), and GLP-1
analogues have actions with the potential to significantly improve glycemic
control in patients with diabetes. Evidence suggests that these agents use ... Cited by 185 - Related articles - All 7 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & Metabolism, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age
56 ± 10 years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ±
1.0% (mean ± SD)]. Reduction in A1C from baseline to week 30 [-0.9 ± 0.1% ... Cited by 172 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent
glucose-dependent insulinotropic and glucagonostatic actions, trophic effects on
the pancreatic β-cells, and inhibitory effects on gastrointestinal ... Cited by 154 - Related articles - BL Direct - All 5 versions
OG Kolterman, DD Kim, L Shen, JA Ruggles, … - American Journal of Health-System Pharmacy, 2005 - ASHP R UGGLES , P H .D., is Associate Director Medical Writing, Medical Af- fairs; L
ORETTA L. N IELSEN , P H .D., is Senior Medical Writer, Medical Affairs; M ARK
S. F INEMAN , BS, is Senior Director, Clinical Affairs; and A LAIN D. B ... Cited by 139 - Related articles - All 5 versions
